Activation of group 2 innate lymphoid cells has been demonstrated to reduce age-related cognitive decline in mice. They could represent a new therapeutic target for the treatment of neurocognitive diseases.
Browsing: immune response
A recent study has demonstrated that circadian rhythms in mice may control the extent of response to vaccination of CD8 T cells to antigen presentation by dendritic cells.
Researchers have identified natural killer cells as a potential therapeutic target for the treatment of neuropathic pain. The immune cells can selectively degenerate axons, allowing repair of damaged nerves.
The link between emotional processing and our immune responses – as seen in the placebo effect – could lead to new avenues for treating psychiatric diseases, according to research.
Research has demonstrated that boosting the immune system could offer a novel treatment modality for Alzheimer’s disease.
Scientists reveal that a molecule normally used by the immune system to prevent excessive damage may actually contribute to chronic white matter injury.
Analysis of three studies looks at the role of octagam® for chronic inflammatory demyelinating polyneuropathy patients
Editor’s summary considering the effectiveness and tolerability of octagam in patients with chronic inflammatory demyelinating polyneuropathy.
Researchers discover latent human herpes virus 6 may interfere with the brains ability to repair damaged myelin in brain diseases such as multiple sclerosis.
Researchers have found the first evidence that autoimmunity plays a role in Parkinson’s disease, showing that T cells recognize α-synuclein peptides.
NCTalks at AAN 2017: Michael Pender on a new multiple sclerosis treatment targeting Epstein-Barr virus
Michael Pender discusses promising interim findings from a Phase 1 study investigating a novel treatment for multiple sclerosis.